Cerus Earnings Call: Key Takeaways
Cerus delivered 10% revenue growth and positive Phase III Redis results, though regulatory timelines for the INT200 and CE Mark red cells have shifted later.
- Call
- Nov 2, 2026, 4:30 PM ET
ALFA USA Filings
Every alert, straight from SEC EDGAR
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Cerus Corp filings on SEC EDGAR ↗
Filing type
Alerts
Time
3 alerts with these filters
Cerus delivered 10% revenue growth and positive Phase III Redis results, though regulatory timelines for the INT200 and CE Mark red cells have shifted later.
For the quarter ended September 30, 2026, Cerus Corporation reported product revenue of $57.7 million, a 9.5% increase over the prior year, and achieved a narrow net loss of $0.6 million. The company significantly reduced its nine-month net loss from $13.5 million in 2025 to $5.2 million in 2026, driven by higher gross profits and lower research and development expenses.
Cerus Corporation reported Q3 2026 total revenue of $64.0 million, driven by 10% year-over-year growth in product revenue to $57.7 million. The company also announced positive topline Phase 3 results for its INTERCEPT Blood System for red blood cells and generated $3.0 million in operating cash flow during the quarter.
“Our solid performance in Q3 builds upon a strong first half of 2026 and increases our confidence as we approach year-end. Continued growth from our IFC business, core platelet franchise and international INT 200 rollout strengthens our foundation as we work to establish INTERCEPT as the global standard of care.”
Vivek Jayaraman, Cerus’s president and chief executive officer